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MaBACKGROUND Early detection of pulmonary hypertension (PH) in connective tissue disease (CTD) is crucial to ensuring
that patients receive timely treatment for this progressive disease. Exercise stress tests have been used to screen patients
in an attempt to identify early-stage PH. Recent studies have described abnormal mean pulmonary artery pressure
(mPAP)-cardiac output (Q) responses as having the potential to assess the disease state.
OBJECTIVES This study hypothesized that pulmonary circulation pressure-ﬂow relationships obtained by 6-min walk
(6MW) stress echocardiography would better delineate differential progression of PH and predict development of PH
during follow-up.
METHODS We prospectively performed 6MW stress echocardiographic studies in 78 CTD patients (age 58  12 years;
9% male) at baseline and follow-up. All patients underwent yearly echocardiographic follow-up studies for up to 5 years.
RESULTS During a median period of 32 months (range: 15 to 62 months), 16 patients reached the clinical endpoint of
development of PH and none died during follow-up. PH was conﬁrmed by right heart catheterization in all 16 patients
(mPAP $25 mm Hg and pulmonary capillary wedge pressure #15 mm Hg). In a Cox proportional-hazards survival model,
6MW distance (hazard ratio [HR]: 0.99; p ¼ 0.010), early diastolic tricuspid annulus motion velocity (HR: 0.79;
p ¼ 0.025), and DmPAP/DQ by 6MW stress (HR: 1.10; p ¼ 0.005) were associated with development of PH. In sequential
Cox models, a model on the basis of 6MW distance (chi-square, 6.6) was improved by DmPAP/DQ (chi-square: 14.4;
p ¼ 0.019). Using a receiver-operating characteristic curve, we found that the best cutoff value of DmPAP/DQ for
predicting development of pulmonary hypertension was >3.3 mm Hg/l/min.
CONCLUSIONS The 6MW stress echocardiography noninvasively provides an incremental prognostic value of PH
development in CTD. This is a single-center prospective cohort study. Larger multicenter studies are warranted to conﬁrm
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AB BR E V I A T I O N S
AND ACRONYM S
6MW = 6-min walk
CTD = connective tissue
disease
LV = left ventricular
mPAP = mean pulmonary
artery pressure
PH = pulmonary hypertension
Q = cardiac output
TAM = tricuspid annulus
motion
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377detection due to lack of evidence (3). However, recent
studies have described abnormal cardiac output (Q) re-
sponses for increments of mean pulmonary artery
pressure (mPAP) as having the potential to assess the
disease state and functional class (4–7). This concept
can be applied to predict future development of overt
PH. As noninvasive testing is preferable to invasive
measurements for the purpose of screening, an easy
and noninvasive measure of an individual’s pulmo-
nary circulation is required. Exercise and dobutamine
stress echocardiography were widely used in the
clinical setting, but some additional machines/drugsSEE PAGE 385were also needed. In this study, wemeasured echocar-
diographic parameters post-6-min walk (6MW) as a
classical technique for noninvasive stress testing. We
hypothesized that pressure-ﬂow relationships of the
pulmonary circulation obtained by 6MW stress echo-
cardiography would better delineate differential pro-
gression of PH in patients with CTD and predict the
development of PH during follow-up.
METHODS
STUDY POPULATION. We designed a prospective
study to assess the development of PH in patients with
CTD. All patients had systemic sclerosis, systemic
lupus erythematosus, or mixed connective tissue dis-
ease. Deﬁnitions of these diseases were according to
the American College of Rheumatology diagnostic
criteria (8). Consecutive patients who underwent
echocardiographic screening for PH and had a normal
mPAP range (<25 mm Hg) at rest, as estimated by
echocardiography, were recruited at our echocardio-
graphic examination center between January 2010 and
January 2013. Patients with moderate or severe
valvular disease, atrial ﬁbrillation/ﬂutter, left ventric-
ular ejection fraction <50%, signiﬁcant shunts, signif-
icant interstitial lung disease (percent forced vital
capacity<70%), or known coronary artery diseasewere
excluded. Eighty-six patients with CTD underwent
echocardiographic studies pre- and post-6MW. Four
patients were excluded due to lack of a measurable
tricuspid regurgitant jet, and 4 patients were excluded
due to starting PH-speciﬁc therapy after the initial
stress echocardiography. Therefore, 78 patients were
included for ﬁnal analysis. All patients underwent
yearly echocardiographic follow-up studies for up to 5
years. The Institutional Review Board of the University
of Tokushima approved the study protocol, and writ-
ten informed consent was obtained from all subjects.
ECHOCARDIOGRAPHIC ASSESSMENT. Transthoracic
echocardiography was performed by experiencedsonographers/doctors using a commercially
available ultrasound machine (Vivid 9, GE
Vingmed, Horten, Norway). Measurements
and recordings were obtained according to
the American Society of Echocardiography
recommendations (9). Left ventricular (LV)
end-diastolic volume, LV end-systolic vol-
ume, left atrial volume, and LV ejection
fraction were calculated by the biplane
Simpson disk method using 2-dimensional
images and indexed to body surface area.
The early diastolic mitral annular tissue
velocity (é) was measured in the apical
4-chamber view, with the sample volume positioned
at the lateral mitral annulus motion and lateral
tricuspid annulus motion (TAM). Standard echocar-
diographic measurements of the right ventricle (RV)
were made in accordance with current guidelines
(10). RV fractional area change was deﬁned using the
formula: (end-diastolic area end  systolic area)/end-
diastolic area  100. Systolic PAP was measured from
the maximal continuous-wave Doppler velocity of the
tricuspid regurgitant jet using the systolic trans-
tricuspid pressure gradient calculated by the modi-
ﬁed Bernoulli equation. Right atrial pressure was
estimated from the inferior vena cava diameter and
collapsibility (11). The mean PAP was calculated as:
0.6  systolic PAP þ 2 (12).
6MW STRESS ECHOCARDIOGRAPHY. The 6MW test
was performed indoors along a ﬂat, straight, enclosed
corridor with a hard surface (13). The walking course
was 50 m in length. The transcutaneous arterial oxy-
gen saturation was determined by pulse oximetry.
The peak tricuspid regurgitation jet was obtained by
echocardiography post-6MW (within 10 s). Q was ob-
tained from electric cardiometry (Aesculon Electrical
Velocimetry, Osypka Medical GmbH, Berlin, Ger-
many) at the same time (14). In the previous study,
the agreement between Q by electric cardiometry and
by pulmonary artery catheter was clinically accept-
able (15). In our cohort with invasive data (n ¼ 16),
there is a good correlation between right heart cath-
eterization (RHC) and electric cardiometry values of Q
(r ¼ 0.85; p < 0.001) with electric cardiometry mea-
surements slightly underestimating Q (the mean Q
was 4.5  1.0 l/min, the mean bias was 0.6 l/min
[14% of the mean], and the 95% conﬁdence interval
[CI] was 0.26 to 0.91) (Online Figure). We have
calculated the PAP-Q relationships as mPAP divided
by Q (mPAP/Q) and the slope of mPAP/Q in individual
patients (DmPAP/DQ) (Figure 1).
CLINICAL OUTCOMES. The duration of follow-up was
begun at the time of the initial stress echocardiogram
FIGURE 1 Representative Recordings of Doppler Echocardiography and Electric Cardiometry at Baseline and Post-6MW
ΔmPAP/ΔQ = (18.2–11.6)/(8.3–4.9) = 1.94 mm Hg/l/min
Baseline
Post 6MW
Cardiac Output (electric cardiometry)Tricuspid valve regurgitation
TR-V: 2.0 m/sec
mPAP: 11.6 mm Hg
TR-V: 2.6 m/sec
mPAP: 18.2 mm Hg
TR-V was accelerated and Q was increased post-6MW. We calculated the pulmonary artery pressure-cardiac output relationships as DmPAP
divided by DQ (DmPAP/DQ). 6MW ¼ 6-min walk; mPAP ¼ mean pulmonary arterial pressure; Q ¼ cardiac output; TR-V ¼ tricuspid valve
regurgitation velocity.
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378and ended in January 2015. Development of PH at
rest was the primary endpoint. During longitudinal
analysis, patients were referred for RHC if the
mPAP was $25 mm Hg at rest on yearly follow-up
echocardiography with clinical symptoms. On RHC,
development of PH was deﬁned as mPAP $25 mm Hg
(3,16).
STATISTICAL ANALYSIS. Data are presented as
mean  SD. The Student t test was used to com-
pare continuous variables; the chi-square test was
applied to compare categorical variables. To assess
prognostic value, median values of DmPAP/DQ
(3.1 mm Hg/l/min) and 6MW distance (480 m)
were used to divide patients into 2 groups for
Kaplan-Meier analysis, with event-free survival
compared using a 2-sided log-rank test. Cox
proportional-hazards survival models in univariable
and multivariable analyses were used to identify the
association between 6MW distance and echocardio-
graphic parameters with outcomes. To avoid over-
ﬁtting the model, we added only 1 echocardiographic
variable into the model using the 6MW distance;
interaction terms between variables were notentered. We entered 6MW distance and DmPAP/DQ
into the ﬁnal model. Sequential Cox models were
performed to determine the incremental prognostic
beneﬁt of DmPAP/DQ over the 6MW distance, with
incremental prognostic value being deﬁned by a sig-
niﬁcant increase in global chi-square. A hazard ratio
(HR) with a 95% CI was calculated for each variable.
The scaled Schoenfeld residuals for each independent
variable were plotted against time to assess the
assumption of proportional hazards; these correla-
tions were found to be nonsigniﬁcant. Receiver-
operating characteristic curves were generated to
determine optimal cutoff values of continuous vari-
ables. The best cutoff value was deﬁned as the upper
limit of the CI of the Youden index. To assess differ-
ences in development of PH between groups, we
applied a linear mixed-effects model with unstruc-
tured covariance for random effects using standard
statistical software (SPSS software 20.0, SPSS Inc.,
Chicago, Illinois) (17,18). We used DmPAP/DQ and
6MW distance as factors, time after initial echocar-
diographic assessment as a covariate, and their ﬁrst-
degree interactions (time  severity of DmPAP/DQ
TABLE 2 Hemodynamic Variables
Baseline Post 6-Min Walk
LVEDV, ml 74  19 –
LVESV, ml 25  7 –
LVEF, % 66  3 –
LAVi, ml/m2 27  9 –
MAM-é, cm/s 10.3  2.8 –
E/e0 6.9  2.5 –
RVEDA, cm2 12.3  3.1 –
RVESA, cm2 6.8  1.9 –
RVFAC, % 44  10 –
TAM-é, cm/s 9.9  2.9 –
Mean PAP, mm Hg 19  3 25  4
Cardiac output, l/min 4.3  1.2 7.4  2.8
mPAP/Q, mm Hg/l/min 4.8  1.5 3.9  1.7
DmPAP/DQ, mm Hg/l/min – 3.4  4.4
Values are mean  SD.
E/é ¼ the ratio of early diastolic transmitral ﬂow velocity to early diastolic mitral
annular motion; LAVi ¼ left atrial volume index; LVEDV ¼ left ventricular end-
diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventric-
ular end-systolic volume; LVSDV ¼ left ventricular end-systolic volume; MAM-é ¼
early diastolic mitral annular motion; mPAP ¼ mean pulmonary artery pressure;
Q ¼ cardiac output; RVEDA ¼ right ventricular end-diastolic area; RVESA ¼ right
ventricular end-systolic area; RVFAC ¼ right ventricular fractional area change;
TAM-é ¼ early diastolic tricuspid annular motion.
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379and 6MW distance), with the signiﬁcance of the cor-
responding parameter estimates reported in the re-
sults. Interobserver and intraobserver variability was
examined for DmPAP/DQ. Measurements were per-
formed in a group of 20 randomly selected subjects by
1 observer and then repeated on 2 separate days by 2
observers who were unaware of the measurements of
the others and of the study time point. Reproduc-
ibility was expressed as the mean percentage error
(absolute difference divided by the average of the 2
observations). Statistical signiﬁcance was deﬁned by
p < 0.05.
RESULTS
PATIENT CHARACTERISTICS. Baseline characteris-
tics of the study group are presented in Table 1.
Systemic sclerosis was the most common underlying
CTD (70%), followed by systemic lupus erythemato-
sus (20%) and mixed connective tissue disease
(10%). Blood pressure and heart rate at baseline
were well-controlled in this cohort (heart rate: 73 
12 beats/min and systolic blood pressure: 126 
20 mm Hg). Post-6MW, heart rate, blood pressure,
output, and mPAP were increased. Echocardio-
graphic variables are shown in Table 2. The average
DmPAP/DQ was 3.4  4.4 mm Hg/l/min. The intra-
observer variability for the measurement of DmPAP/
DQ was 5.6%  3.8%; interobserver variability was
7.2%  5.1%.TABLE 1 Clinical Variables (N ¼ 78)
Age, yrs 58  12
Male 7 (9)
Body surface area, m2 1.5  0.1
Diagnosis
Systemic sclerosis 54 (70)
Systemic lupus erythematosus 16 (20)
Mixed connective tissue disease 8 (10)
%FEV1, % 88  17
%FVC, % 101  13
Baseline hemodynamics
Heart rate, beats/min 73  12
Systolic blood pressure, mm Hg 126  20
Diastolic blood pressure, mm Hg 73  12
SpO2, % 98  1
Post 6-min walk hemodynamics
Heart rate, beats/min 98  21
Systolic blood pressure, mm Hg 133  24
Diastolic blood pressure, mm Hg 75  14
SpO2, % 96  3
6-min walk distance, m 479  99
Values are mean  SD or n (%).
%FEV1 ¼ percent forced expiratory volume in 1 s; %FVC ¼ percent forced vital
capacity; SpO2 ¼ percutaneous oxygen saturation.EVENT-FREE SURVIVAL. During a median period
of 32 months (range 15 to 62 months), 16 patients
reached the clinical endpoint of the development of
PH and no patients died during follow-up. PH was
conﬁrmed by RHC in all 16 patients (mPAP $25 mm Hg
and pulmonary capillary wedge pressure #15 mm Hg)
(Table 3). Eighteen patients underwent RHC because of
a positive screening on echocardiography (mPAP $25
mm Hg at rest). Figure 2A illustrates the time to PH
development in patients with CTD and stratiﬁed ac-
cording to median values of 6MW distance (480 m).
Figure 2B illustrates the time to PH development
stratiﬁed according to median values of DmPAP/DQ
(3.1 mm Hg/l/min). Patients with impaired 6MW
distance and increased DmPAP/DQ had signiﬁ-
cantly shorter event-free survival than those with-
out impaired 6MW distance or increased DmPAP/DQTABLE 3 Invasive Hemodynamic Data (N ¼ 16)
Age, yrs 60  15
Male 3 (23)
Heart rate, beats/min 69  9
Systolic blood pressure, mm Hg 124  15
Diastolic blood pressure, mm Hg 72  8
Mean pulmonary artery pressure, mm Hg 30  3
Mean pulmonary capillary wedge pressure, mm Hg 9  3
Cardiac output, l/min 4.8  1.1
Pulmonary vascular resistance, wood units 4.7  1.8
Values are mean  SD or n (%).
FIGURE 2 Kaplan-Meier Analysis of Event-Free Survival
p=0.001
ΔmPAP/ΔQ ≥median
ΔmPAP/ΔQ ≥median
ΔmPAP/ΔQ <median
ΔmPAP/ΔQ <median
100
80
60
40
20
0
10 20 30 40 50 60
Months
Number at risk
39 31 28 14 7 4
1513182939
De
ve
lo
pm
en
t P
H 
(%
)
B
100
80
p=0.03
6MW distance ≤median
6MW distance >median
60
40
20
10 20 30
Months
Number at risk
6MW distance >median
39 36 29 16 10 3
2211172439
6MW distance ≤median
De
ve
lo
pm
en
t P
H 
(%
)
A
40 50 60
p<0.001
100
80
60
40
20
0
10 20 30 40 50 60
Time
Number at risk
A
B
C
20
38
20
19
29
12
17
23
6
9
12
6
6
5
1
3
1
1
A: 6MW distance >median
& ΔmPAP/ΔQ <median
B: 6MW distance ≤median
or ΔmPAP/ΔQ ≥median
C: 6MW distance ≤median
& ΔmPAP/ΔQ ≥medianDe
ve
lo
pm
en
t P
H 
(%
)
C
Patients were stratiﬁed according to decreased 6MW distance (A) and increased DmPAP/DQ (B) and both variables (C). PH ¼ pulmonary
hypertension; other abbreviations as in Figure 1.
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380(p < 0.001) (Figure 2C). The Central Illustration shows
multipoint mPAP and Q plots at baseline and post
6MW. The DmPAP/DQ in patients with events (devel-
opment of PH)was signiﬁcantly higher than in patients
without events (6.1  3.8 mm Hg/l/min vs. 2.6  4.3
mm Hg/l/min; p < 0.001). Using a receiver-operating
characteristic curve, we found that the best cutoff
value of DmPAP/DQ for predicting the development of
pulmonary hypertension was >3.3 mm Hg/l/min.
PREDICTING TIME TO PH DEVELOPMENT. Hazards
ratios of the relevant parameters are shown in
Table 4. The 6MW distance (HR: 0.99; 95% CI: 0.98 to
0.99; p ¼ 0.010), peak early diastolic TAM velocity
(TAM-é) at baseline (HR: 0.79; 95% CI: 0.64 to 0.97;p ¼ 0.025), mPAP/Q at baseline (HR: 1.50; 95% CI: 1.05
to 2.13; p ¼ 0.025), mPAP post-6MW (HR: 1.15; 95% CI:
1.05 to 1.25; p ¼ 0.002), Q post-6MW (HR: 0.72; 95%
CI: 0.53 to 0.96; p ¼ 0.026), mPAP/Q post-6MW (HR:
1.49; 95% CI: 1.21 to 1.85; p ¼ 0.001), and DmPAP/DQ
(HR, 1.10; 95% CI: 1.04 to 1.16; p ¼ 0.005) were asso-
ciated with time to development of PH. In sequen-
tial Cox models, a model based on 6MW distance
(chi-square ¼ 6.6) was improved by DmPAP/DQ
(chi-square ¼ 14.4; p ¼ 0.019). For the Cox model
based on 6MW distance, the Harrell C concordance
statistic was calculated to be 0.64. When DmPAP/DQ
is added to the models, the C statistic improves to
0.78 (p ¼ 0.046).
CENTRAL ILLUSTRATION Development of Pulmonary Hypertension in Connective Tissue Disease:
Individual Multipoint mPAP and Cardiac Output Plots
Kusunose, K. et al. J Am Coll Cardiol. 2015; 66(4):376–84.
Individual, pre- and post-6-min walk, multipoint mPAP, and Q plots (A). The slope of mPAP-Q (DmPAP/DQ) in patients with event (development
of PH) (B)was signiﬁcantly higher than in patients without event (C). CTD¼ connective tissue disease;mPAP¼mean pulmonary arterial pressure;
PH ¼ pulmonary hypertension; Q ¼ cardiac output.
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TABLE 4 Univariable Associations of PH Development
Development of PH
HR (95% CI) p Value
SSc 0.70 (0.22-2.25) 0.56
6MW distance 0.99 (0.98-0.99) 0.010
LV function
LVEDV, ml 0.99 (0.96-1.03) 0.67
LVESV, ml 0.99 (0.91-1.08) 0.81
LVEF, % 0.95 (0.78-1.15) 0.57
LAVi, ml/m2 1.01 (0.93-1.09) 0.91
MAM-é, cm/s 0.92 (0.77-1.09) 0.32
E/é 1.18 (0.94-1.48) 0.15
RV function
RVEDA, cm2 0.95 (0.69-1.28) 0.72
RVESA, cm2 0.74 (0.51-1.08) 0.12
RVFAC, % 0.98 (0.89-1.07) 0.98
TAM-é, cm/s 0.79 (0.64-0.97) 0.025
mPAP, mm Hg 1.11 (0.98-1.25) 0.09
Cardiac output, l/min 0.74 (0.45-1.20) 0.22
mPAP/Q, mm Hg/l/min 1.50 (1.05-2.13) 0.025
Post-6MW
mPAP, mm Hg 1.15 (1.05-1.25) 0.002
Cardiac output, l/min 0.72 (0.53-0.96) 0.026
mPAP/Q, mm Hg/l/min 1.49 (1.21-1.85) 0.001
DmPAP/DQ, mm Hg/l/min 1.10 (1.04-1.16) 0.005
Bold represents statistically signiﬁcant.
6MW ¼ 6-min walk; LV ¼ left ventricular; PH ¼ pulmonary hypertension;
RV ¼ right ventricular; SSc ¼ systemic sclerosis; other abbreviations as in Table 2.
Kusunose et al. J A C C V O L . 6 6 , N O . 4 , 2 0 1 5
Development of Pulmonary Hypertension in CTD J U L Y 2 8 , 2 0 1 5 : 3 7 6 – 8 4
382ECHOCARDIOGRAPHIC FOLLOW-UP. As expected on
the basis of parameter estimates obtained by the
mixed-effects model, mPAP at rest was similar in
patients with higher and lower DmPAP/DQ groups at
the beginning of the follow-up (p ¼ 0.92). The mPAP
in patients with higher DmPAP/DQ signiﬁcantly in-
creased at a rate of 1.0  0.4 mm Hg/year (p ¼ 0.014).
In patients with lower DmPAP/DQ, there was no sig-
niﬁcant change in mPAP over time (Figure 3A). With
the mixed-effects model, there is no difference of
mPAP between longer and shorter 6MW distances at
the beginning of follow-up; no signiﬁcant change
between the 2 groups was noted during follow-up
(Figure 3B).
DISCUSSION
We demonstrated that DmPAP/DQ obtained by 6MW
stress echocardiography was a predictor of future
development of PH in patients with CTD and was in-
dependent of 6MW distance. Additionally, there was
progressive PH in the higher DmPAP/DQ group. This
progression further implies the presence of subclini-
cal impaired pulmonary circulation in these patients
at an early stage of PH. Therefore, our results suggest
the importance of yearly follow-up echocardiographyin CTD patients in the higher DmPAP/DQ group.
The classical, but novel application of 6MW stress
echocardiography for pulmonary circulation is a
noninvasive technique that can be used to detect
abnormal mPAP-Q responses.
PREDICTOR OF PROGRESSIVE PH. The management
of CTD for the development of PAP remains a matter
of debate because of limited data on progressive PH
(19). In general, the large reserve of the pulmonary
circulation indicates that PH is usually diagnosed late
in its course, with an asymptomatic stage preceding
onset (5). Thus, patients with early PH may present
with almost normal resting mPAP, but an abnormal
exercise mPAP, with an increase in pulmonary blood
ﬂow. Our study demonstrated that patients with CTD
had a median DmPAP/DQ of 3.1 mm Hg/l/min as a
surrogate of pulmonary circulation. Invasive as well
as noninvasive studies in healthy volunteers showed
that the slopes of mPAP-Q relationships range from
0.5 to 3 mm Hg/l/min and the average was 1.5  0.3
mm Hg/l/min (6). This result supported our cutoff
DmPAP/DQ value. In addition, several studies have
previously described the clinical utility of mPAP-Q
assessment. The mPAP-Q was associated with 6MW
distance and functional class compared with the
resting echocardiographic parameters (4,7). There-
fore, assessment of pulmonary circulation provides
important clinical information. We also showed the
prognostic value of RV function (TAM-é) in our
cohort. There has recently been increasing recogni-
tion of the prognostic information provided by RV
function in heart failure and PH (20–22). Our results in
this study are consistent with previous work linking
RV function with the development of PH in patients
with CTD.
PATHOGENESIS OF PROGRESSIVE PH. The cause of
impaired pulmonary circulation in CTD is not well-
characterized (23). CTDs are deﬁned as systemic,
nondegenerative, non-neoplastic, noninfectious in-
ﬂammatory diseases and cause interstitial ﬁbrotic
degeneration. Pulmonary circulation depends mainly
on the inability of the pulmonary vascular bed to
dilate under stress and, consequently, reﬂects the
abnormally stiff vascular system characteristic of
CTD. Our data suggest that this inability of the pul-
monary vascular bed to dilate under stress is pre-
dictive of PH during follow-up. Conversely, CTD
etiology was not signiﬁcantly associated with
development of PH in the present study. A possible
explanation for this is the relatively small sample
size. Therefore, our ﬁndings may not be extrapolated
to all patients with CTD. In addition, PH related to
CTD can be associated with occult left-sided diastolic
FIGURE 3 Follow-Up Data for mPAP
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We stratiﬁed this population according to and increased DmPAP/DQ (A) and decreased
6MW distance (B). Error bars show 1 standard error of the mean. Abbreviations as in
Figure 1.
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383dysfunction (24). In our cohort, there were no
patients with PH secondary to left heart involve-
ment because all 16 patients on RHC had pulmonary
capillary wedge pressure #15 mm Hg (average: 9 
3 mm Hg).
TIME COURSE OF PH IN CONNECTIVE TISSUE DISEASE.
Understanding the time course of PH in patients
with CTD is an essential part of any management plan
(19). There is little available to inform the progression
of PH in CTD not yet deemed to necessitate PH-
speciﬁc medication. Our result showed that PAP
continuously increased in patients with higher
DmPAP/DQ. Once a pulmonary circulation threshold
for DmPAP/DQ is exceeded, rapid decline occurs.
Speciﬁcally, when DmPAP/DQ is >3.1 mm Hg/l/min,
progressive deterioration can be expected in the
coming years. Increasing DmPAP/DQ may be related
to the impaired pulmonary vascular bed and devel-
opment of PAP during follow-up. Therefore, the
likely culprit of deleterious and continuous PAP is
eventual development and worsening of the pul-
monary vascular bed. The long-term dysfunction of
pulmonary circulation may result in progressive PH.
These data suggest that subclinical dysfunction of
the pulmonary vascular bed may be present in some
patients at baseline and be subsequently manifested
by PH. Finally, endothelin receptor antagonists have
been used for early-stage PH (25). We hope that
clinical trials will be planned to assess the effects
of these medications for patients at high risk of PH
development.
CLINICAL IMPLICATIONS. Our results add an alter-
native tool to assess the right heart pulmonary cir-
culation in the clinical setting in patients suspected to
have PH. The 6MW stress echocardiography re-
presents a potential method for early diagnosis of PH
in CTD individuals. Subjects at higher risk, such
as those with increased DmPAP/DQ, are known to
have an abnormal rise in PAP during follow-up. The
6MW stress echocardiography may prove to be a
noninvasive surrogate to assess capillary reserve, and
different responses may be seen in the progression of
different diseases.
STUDY LIMITATIONS. The sample size was small,
with relatively few events, which poses a potential
risk of model overﬁt. PAP was measured on the basis
of echocardiographic parameters, which have
inherent measurement variability. A further limita-
tion is that echocardiographic imaging after exercise
is operator-dependent and, therefore, should be
performed by experts. We may not have been able to
avoid the potential inclusion of patients having occult
PH at baseline because none had RHC. There may bephysiological differences with another type of exer-
cise protocol (e.g., supine bicycle or treadmill test).
These ﬁndings may not be interchangeable with
another exercise protocol type. Some impact of
worsening of other cardiac factors (ischemic/diastolic
dysfunction) may not be excluded because progres-
sive remodeling leads to a cycle of further PH. Thus,
the present study should be considered as a proof of
concept, and we believe that larger prospective
multicenter studies are warranted.
CONCLUSIONS
We have demonstrated that DmPAP/DQ using 6MW
stress echocardiography as a marker of functional
state of the pulmonary circulation is a good pre-
dictor of PH development in CTD. This technique
is potentially more practical than other stress
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In
patients with connective tissue disease undergoing
stress echocardiography during a 6-min walk, the ra-
tio of DmPAP/DQ is associated with later develop-
ment of PH and its progression and is an indicator of
subclinical pulmonary circulatory impairment.
TRANSLATIONAL OUTLOOK: Further studies are
necessary to assess the effect of therapeutic inter-
ventions in patients with connective tissue disease
and impaired pulmonary circulation.
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384echocardiographies. In addition, there was progres-
sive PH in patients with higher DmPAP/DQ, which
further implies the presence of subclinical impaired
pulmonary circulation at an early stage of PH in
these patients.
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